tRNA-derived small RNAs: novel regulators of cancer hallmarks and targets of clinical application

Xizhe Li1,2,6, Xianyu Liu1,2,6, Deze Zhao1,2, Weifang Cui1,2, Yingfang Wu3, Chunfang Zhang1,2,4 and Chaojun Duan1,2,5

© The Author(s) 2021

tRNAs are a group of conventional noncoding RNAs (ncRNAs) with critical roles in the biological synthesis of proteins. Recently, tRNA-derived small RNAs (tsRNAs) were found to have important biological functions in the development of human diseases including carcinomas, rather than just being considered pure degradation material. tsRNAs not only are abnormally expressed in the cancer tissues and serum of cancer patients, but also have been suggested to regulate various vital cancer hallmarks. On the other hand, the application of tsRNAs as biomarkers and therapeutic targets is promising. In this review, we focused on the basic characteristics of tsRNAs, and their biological functions known thus far, and explored the regulatory roles of tsRNAs in cancer hallmarks including proliferation, apoptosis, metastasis, tumor microenvironment, drug resistance, cancer stem cell phenotype, and cancer cell metabolism. In addition, we also discussed the research progress on the application of tsRNAs as tumor biomarkers and therapeutic targets.

Cell Death Discovery (2021) 7:249; https://doi.org/10.1038/s41420-021-00647-1

FACTS

- tsRNAs are a novel group of ncRNAs that have critical biological functions through translation modification, miRNA-like functions, and their interaction with PIWI proteins.
- tsRNAs are widely and abnormally expressed in tumor tissues and can regulate the biological hallmarks of cancer cells.
- The application of tsRNAs as biomarkers and therapeutic targets of cancer is an emerging topic in cancer research.

QUESTIONS

- How are all these types of tsRNAs cleaved by ribonucleases?
- What is the general pattern of biological functions of tsRNAs that are involved with proteins other than AGOs?
- What are the exact functions of tsRNAs in the tumor microenvironment?

INTRODUCTION

Noncoding RNAs (ncRNAs) that are not translated exist widely in mammalian cells. Small ncRNAs (sncRNAs) are a group of ncRNAs up to 200 nucleotides (nt) in length that include microRNAs (miRNAs), small interfering RNAs (siRNAs), and small nucleolar RNAs (snoRNAs), and have various biological functions in multiple cellular processes. These sncRNAs have been shown to mediate multiple biological functions by RNA silencing, translation regulation, and many other molecular mechanisms.

Transfer RNAs (trRNAs) are a group of classic ncRNAs and are well known for the translation of amino acids to messenger RNAs (mRNAs) [1]. In addition to protein synthesis, trRNAs are also involved in cell proliferation and tumorigenesis [2]. Mature trRNAs are ~70–90 nt with a D-loop, a TΨC loop, an anti-codon loop, a variable loop, and an acceptor arm. There are many lines of evidence demonstrating that the dysregulation of genes is related to the posttranscriptional modification of tRNA, and cytoplasmic tRNA-related proteins are associated with human diseases [3].

With the breakthrough of high-throughput sequencing and microarray technologies, abundant novel small ncRNAs types were found. In 1979, tRNA-derived small RNAs (tsRNAs) were first found in cancer patients [4]. tsRNAs were initially considered as random degradation products during tRNA biogenesis and degradation. However, gradually accumulating evidence has shown that tsRNAs have few relationships with parental tRNA abundance. They are produced by specific nucleases at the specific site of mature or pre-tRNAs and are closely related to metabolism, viral infection, neurodegeneration, and tumorigenesis [5–11]. Like miRNAs, tsRNAs were widely detected in cells from most types of cancer tissues. Recent studies showed that tsRNAs play crucial roles in cell proliferation, apoptosis, metabolism, metastasis, and other
characteristics of most cancer types by participating in various molecular processes such as protein synthesis, gene silencing, and RNA processing. Meanwhile, tsRNAs have attracted much attention because of their potential application as biomarkers and therapeutic targets of tumor diseases. Therefore, these findings demonstrate that tsRNAs can be new regulatory factors for the hallmarks of cancer.

In this review, we will discuss the characteristics of tsRNAs, dysregulation of tsRNAs in tumor cells, and explore the regulatory roles of tsRNAs in cancer biological functions. In addition, we will also discuss the application opportunity of tsRNAs as tumor biomarkers and therapeutic targets.

CLASSIFICATION AND BIOGENESIS OF TSRNAS

In recent years, many researchers focused on tsRNA-related studies. However, these researchers promoted their own nomenclature for tsRNAs without a unified principle. Therefore, the nomenclature of tsRNAs is confusing and redundant. Herein, we will discuss the main classifications of tsRNAs, and elucidate the relationship between these subtypes. tsRNAs are cleaved from precursor or mature tRNAs with a length of 18–40 nt and include two major components: tRNA halves and tRNA-related small RNA fragments (tRFs). tRNA halves are longer at 30–40 nt. tRFs are shorter and have a length of 18–30 nt (Fig. 1). Meanwhile, researchers suggest that all these types of tsRNAs are closely intertwined with miRNAs in cancer cells [12].

tRNA halves were first described in 1969, and named because their structure is almost half that of mature tRNAs [13]. They are more commonly called tRNA-derived stress-induced RNAs (tiRNAs) because their biogenesis largely occurs under conditions of stress such as hypoxia, oxidative stress, heat shock and nutritional deficiency [14, 15]. Mature tRNAs are cleaved into 5′-tRNA halves (5′-tiRNAs) and 3′-tRNA halves (3′-tiRNAs) at the anticodon loops by angiogenin (ANG). 5′-tiRNAs are cleaved from the 5′-end of mature tRNA to the end of the anticodon loop, and 3′-tiRNA starts at the nucleotide in the anti-codon loop and proceeds to the 3′-ends of mature tRNAs [16].

tRFs consist of tRF-5s, tRF-3s, tRF-1s (3′U-tRFs), and tRF-2s (i-tRFs). tRF-5s, tRF-3s, and tRF-2s are the products of mature tRNA cleavages, and tRF-1s are cut from pre-tRNAs. A tRF-5s (14–30 nt) is derived from the 5′-end of a mature tRNA and ends in the D-loop (tRF-5a) or at a stem region between the D-loop and the anti-codon loop (tRF-5b and tRF-5c) of mature tRNAs. They can be classified into three specific lengths, tRF-5a (14–16 nt), tRF-5b (22–24 nt), and tRF-5c (28–30 nt) [17]. A tRF-3s is generated from the TψC loop to the “CCA” tail and mainly contains two subtypes: tRF-3a and tRF-3b. The difference between these two subtypes is the sequence length. Members of the tRF-3b family are ~4 nt longer than members of the tRF-3a family and can be 22-nt long [18]. Previously, tRF-5s and tRF-3s were identified as Dicer-dependent products, whereas further studies found that ANG and other members of the ribonuclease A superfamily also participate in the cleavage of these tRFs [17, 19].

tRF-1s (16–48 nt) are derived from the 3′-end of the precursor tRNA in the nucleus by the ribonuclease Z (RNaseZ) or in the cytoplasm by the homologous ribonuclease Z2 (ELAC2) [20, 21]. Both tRF-1s and tRF-3s are shorter than tRF-5s and tRF-2s, but have diverse biological functions because of the difference in 5′-ends [22]. The length of tRF-1s is more diverse than that of other tRFs because of the various positions that endonucleases recognize. Unlike the tRFs described above, tRF-2s (i-tRFs) are a newly discovered type of tRF that are generated from the internal region of mature tRNAs straddling the anti-codon region with variable length [23]. Thus far, the synthesis of tRF-2s and the ribonucleases that participate in this process are still unclear.

Researchers also name the tsRNAs in studies according to their functional mechanisms. For example, in Honda’s study, the authors defined the abundantly expressed tRNA halves in estrogen receptor (ER)-positive breast cancer and androgen receptor (AR)-positive prostate cancer cell lines as Sex Hormone-dependent tRNA-derived RNAs (SHOT-RNAs) [24]. Meanwhile, another study identified PIWI-interacting tsRNAs as td-piRs [25]. Although the nomenclature of tsRNAs is confusing, there are emerging online databases that summarize and name the validated tsRNAs, such as TRFdb (http://genome.bioch.virginia.edu/trfdb/) and OncotRF (http://bioinformatics.zju.edu.cn/OncotRF) [6, 26].

![Fig. 1](image-url) Classification of tsRNAs. tRF-1s are derived from the 3′-end of the precursor tRNA. tRF-5s are derived from the 5′-end of mature tRNAs and end at a D-loop or at a stem region between the D-loop and the anti-codon loop. tRF-3s are generated from the TψC loop with a “CCA” tail. tRF-2s are produced by decomposition of the anticodon loop of tRNA and do not include the typical 5′-end and 3′-end groups. i-tRFs are generated from the internal region of mature tRNAs straddling the anti-codon region with variable length. tiRNAs are almost half the length of mature tRNAs.

BIOLOGICAL FUNCTIONS OF TSRNAS

The first identified biological function of tsRNAs was gene expression inhibition through miRNA-like silencing. However, recent studies have shown that tsRNAs can bind proteins other than AGOs and exhibit more complicated molecular functions. Herein, we will introduce the three major tsRNA-induced molecular mechanisms (Fig. 2).

Translation modulation

tsRNAs are thought to repress mRNA translation in *Halofex volcanii*, in which a subset of 26 nt trf-5s play significant roles [27]. A study showed that the conserved residues in tRNAs were critical components for the appropriate 3-dimensional folding and recognition by the translation machinery [22]. In a subsequent study, Sobala et al. found that tRF-5s contained a conserved GG dinucleotide sequence necessary for translation inhibition [28].

Cell Death Discovery (2021) 7:249
Base modification is one of the vital determinants of the biogenesis and function of tsRNAs. The cytosine-5 RNA methyltransferase NSUN2 is highly expressed in epithelial tumors. The loss of cytosine-5 RNA methylation (m5c) due to NSUN2 deficiency promotes the ANG-induced cleavage of tRNA and leads to an accumulation of 5′-tRNA halves. Meanwhile, the accumulated 5′-tRNA halves in Nsun2−/− cells inhibit mRNA translation rates, promote the activation of stress pathways, decrease cell size and increase cell death [29]. Similarly, Ivanov et al. revealed that 5′-tiRNAs impede protein translation in osteosarcoma cells by displacing the initiation factors eIF4G/eIF4A and eIF4F from mRNA [30]. Another study by Emara et al. revealed that 5′-tiRNAs induced by ANG repressed translation initiation and promoted the phospho-eIF2α-independent assembly of stress granules (SGs) [31]. In addition, Guzzi et al. also found that tRF-5s with TOG, such as tRNA-Ala, tRNA-Cys, and tRNA-Val were significantly absent in PUS7-KO cells, and these tRFs mediated protein biosynthesis and defective germ layer specification in embryonic stem cells. Moreover, the pseudouridine writer PUS7 activated this tRF-mediated translation regulation [32]. In addition, Lyons and his colleagues also demonstrated that RNA G-quadruplex (RG4) structures are required for the translation regulatory functions of tsRNAs [33].

**miRNA-like functions**

It has been suggested that some tRFs have a similar 5′ phosphate and a 3′ hydroxyl group as microRNAs (miRNAs) and perform analogous effects [34]. Previous studies suggested that there is cross-mapping between miRNA precursors and tRFs, and conventionally defined mature miRNAs also overlap with tRFs. tRFs associate with Ago by cross-linking the seven base seed sequence at the 5′ end of tRFs and then form a complex with Ago in a tRF-target-Ago manner, which is similar to the behavior of the miRNA-derived RNA-induced silencing complex (RISC) [35]. After mutation of the complementary base pairing region of the target, the original effect of tRF-induced luciferase reporter repression was weakened [36]. The length of the tRF-induced RISC is approximate to the processed miRNA sequence because of the distinct three-dimensional structural performance of tRFs [37]. These lines of evidence suggest that tRFs may be involved in gene-silencing through a miRNA-like mechanism. However, tRF-3s and tRF-5s tend to associate with Ago 1, 3, and 4, but not Ago 2, which is the main effector protein of miRNA-induced RISC [35]. Guan et al. found that tRFs break the conventional 3′ untranslated region (UTR) targeting pattern of miRNAs and target the coding region, 3′ UTRs and 5′ UTRs of mRNAs [38]. Furthermore, tRFs probably lead Ago to associate with the 5′ ends of agotrons (introns of mRNA) [38].

**DICER is a crucial enzyme in miRNA biogenesis. It cleaves the loop in the stem-loop hairpin structure of the pre-miRNA to produce mature miRNAs [39]. After knockdown of DICER1, a tRF cloned from human mature B cells named CU1276 was reduced. This suggested that the Dicer-dependent cleavage step is a typical mechanism for tRF biogenesis [40]. However, in Dicer knockout cells, luciferase repression by tRF-3 remained [36]. This result suggested that Dicer cleavage may not be the only mechanism of tRF biogenesis.**

**piRNA-like functions**

tsRNAs can also participate in gene silencing by associating with the PIWI protein (PIWI) and act as piRNA (P-element-induced
wimpy testis (PIWI)-interacting small RNAs) [41]. A key function of piRNAs is silencing transposon elements [42]. Ts-101 and ts-53 were reported to correlate with PiWI [5]. Compared with those in wild type controls, all members of the H3A1 histone subfamily were downregulated in HEK293-ts101-KO cells. Some tsRNAs from tRNA-Glu, tRNA-Gly, and tRNA-Pro have a similar length to classical piRNAs, so-called t-di.piR. tDi.piR (Glu) can bind the PiWill4 protein to form a complex and then recruit H3K9 methyltransferases to the CD1a (a specific and functional marker of DCs) promoter region. In this way, highly expressed t-di.piR (Glu) enhances CD1a transcription in monocytes [25]. Moreover, a recent study revealed that tsRNAs could be loaded onto Ago proteins and play a role as miRNAs when one of the RBPs, lupus autoantigen (La), was absent [43].

TSRNAS AND CANCER HALLMARKS

With a deeper understanding of tsRNA biological functions, the critical roles of tsRNAs in human diseases have attracted increasing attention. Recent studies have shown that tsRNAs participate in the development of metabolic and neurological diseases and have pivotal functions in vital infections and stress-induced cell damage. Not surprisingly, numerous studies have also revealed that tsRNAs can stimulate malignant progression and regulate tumor cell hallmarks. Herein, we summarized the biological cancer hallmarks that are certainly or potentially regulated by tsRNAs (Table 1).

Dysregulation of tsRNAs

tRF-1001 was the first tsRNA found to be abnormally expressed in a range of cancer cells [21]. After that, many dysregulated tsRNAs in tumor cells were also discovered. tRFs such as ts-3676 and ts-4521 are significantly downregulated and mutated in chronic lymphocytic leukemia (CLL) compared to normal controls [44]. CU1276, one of the tRF-3s, is highly expressed in mature B cells but absent in germinal center-derived lymphomas [40]. Shao et al. found that the expression of tRF-Leu-CAG was significantly upregulated in non-small cell lung cancer (NSCLC) tissues, cell lines and patient serum and positively correlated with tumor stage [45]. tDR-7816, a subtype of t-TRF, and 5′-tRNA-Val were decreased in breast cancer cells [46, 47]. Intriguingly, 30–35 nt long 5′-tRNA halves were increased in chronic viral hepatitis but reduced in liver cancer tissues [48]. In silico analysis of the TCGA-BLCA project identified 5′-tRF-LysCTT as dysregulated in bladder tumors (BICa) [49]. It was significantly elevated in BICa and associated with an aggressive tumor phenotype, early disease progression, and a poor treatment outcome in 230 BICa patients. In addition, three 5′ tRFs were diversely expressed in testicular germ cell tumors compared with normal samples [50].

Cell proliferation

As a well-known core hallmark, the proliferation capacity of cancer cells determines the progression of tumors and the prognosis of patients in a crucial way. In addition, this characteristic is the first cancer hallmark that was found to be associated with tsRNAs. tRF-1001 was the first tsRNA found to be associated with tumor proliferation. tRF-1001 is a prostate cancer susceptibility gene derived from pre-tRNA-Ser that is highly expressed in cancer cells and promotes cell proliferation by regulating the cell cycle [21].

Sex hormones play essential roles in the biogenesis of cancers, especially breast and prostate cancer. One newly identified type of tRF named SHOT-RNA produced by ANG is significantly elevated in estrogen receptor-positive breast cancer and androgen receptor-positive prostate cancer (PCa) cell lines. The cell growth rate was decreased when an siRNA targeting 5′SHOT-RNA was transfected with, and the levels of mature tRNAs were not changed in siRNA transfected cells [24]. These results suggested that SHOT-RNAS have an independent stimulating effect on cancer cell proliferation. Before this, Martens-Uzunova et al. found that 18-nt-long tRFs were significantly increased in PCa tissues by gene sequencing, whereas 27-nt-long tRFs were the most elevated tRFs [51].

tSRNAS also play a vital role in the proliferation of ovarian cancer cells. Small RNA sequencing and PCR results revealed that 27 tRFs were differentially expressed between high-grade serous ovarian cancer (HGSOc) patients and healthy control patients [52]. These tRFs mostly involved in protein phosphorylation, transcription, cell migration, the pathway involved in cancer, and the MAPK/Wnt signaling pathways. Among them, tRF-03357 was upregulated in HGSOc serum samples and SK-OV-3 cells. Furthermore, tRF-03357 promoted the proliferation, migration, and invasion of SK-OV-3 cells by modulating the transcription factor HMBOX1. In addition to tRF-03357, one tRF derived from tRNA-Glu was identified in ovarian cancer. tRNA-Glu-CTC (tRF-Glu) was confirmed to bind directly to a site in the 3′UTR of the Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) mRNA and hence reduce its expression, ultimately inhibiting the proliferation of ovarian cancer cells [53].

After transfection with a tRF-Leu-CAG inhibitor, the proliferation capacity of lung cancer cells decreased, the number of cells in the G0/G1 phase increased, and the expression of aurinal kinase A (AURKA) protein increased significantly [45]. AURKA is a highly conserved serine kinase/threonine kinase that participates in the control of the cell cycle and is related to the regulation of some cell division-related biological processes [54]. Previous studies have shown that miRNA-137 and miRNA-32 can affect the progression of NSCLC by acting on AURKA [54, 55].

CU1276 is a representative tRF-3 that is overexpressed in mature B cells but repressed in lymphoma cell lines [40]. Stable expression of CU1276 in Burkitt lymphoma cells can inhibit cell proliferation, and when exogenous RPA1 is coexpressed, the proliferation of lymphoma cells can be restored. Similarly, the strong expression of CU1276 leads lymphoma cells to become more sensitive to drug-induced DNA damage. Restoration of RPA1 levels impeded this sensitization. These results suggested that CU176 inhibits lymphoma cell proliferation and is involved in DNA damage in an RPA1-dependent manner [40, 56].

Moreover, there is evidence suggesting that tRFs and tRNAs may regulate gene expression by binding to RBPs. tRFs from tRNA-Asp, tRNA-Glu, tRNA-Tyr, and tRNA-Gly can suppress cell growth under serum-starvation conditions by binding to YBX1, an RBP with multiple biological functions, and repressing its combination with some endogenous oncogene transcripts in breast cancer [57].

Cell apoptosis

The resistance to apoptosis, or programmed cell death, is another important trait that allows cancer cells to expand their population and escape drug-induced extinction. Since tsRNAs are derived from tRNA, it can be inferred that tsRNAs may share some functions with tRNAs. Previous evidence suggested that tRNAs inhibit apoptosis by binding to cytochrome C (Cyt c) [58]. Saikia et al. found that Cyt c could directly bind to tRNAs to form a ribonucleoprotein complex, block the oligomerization of Apaf-1 to ultimately inhibit the proliferation of ovarian cancer cells [53]. Resistance 3 (BCAR3) mRNA and hence reduce its expression, ultimately inhibiting the proliferation of ovarian cancer cells [53].

AURKA is a highly conserved serine kinase/threonine kinase that participates in the control of the cell cycle and is related to the regulation of some cell division-related biological processes [54]. Previous studies have shown that miRNA-137 and miRNA-32 can affect the progression of NSCLC by acting on AURKA [54, 55].

CU1276 is a representative tRF-3 that is overexpressed in mature B cells but repressed in lymphoma cell lines [40]. Stable expression of CU1276 in Burkitt lymphoma cells can inhibit cell proliferation, and when exogenous RPA1 is coexpressed, the proliferation of lymphoma cells can be restored. Similarly, the strong expression of CU1276 leads lymphoma cells to become more sensitive to drug-induced DNA damage. Restoration of RPA1 levels impeded this sensitization. These results suggested that CU176 inhibits lymphoma cell proliferation and is involved in DNA damage in an RPA1-dependent manner [40, 56].

Moreover, there is evidence suggesting that tRFs and tRNAs may regulate gene expression by binding to RBPs. tRFs from tRNA-Asp, tRNA-Glu, tRNA-Tyr, and tRNA-Gly can suppress cell growth under serum-starvation conditions by binding to YBX1, an RBP with multiple biological functions, and repressing its combination with some endogenous oncogene transcripts in breast cancer [57].

Cell apoptosis

The resistance to apoptosis, or programmed cell death, is another important trait that allows cancer cells to expand their population and escape drug-induced extinction. Since tsRNAs are derived from tRNA, it can be inferred that tsRNAs may share some functions with tRNAs. Previous evidence suggested that tRNAs inhibit apoptosis by binding to cytochrome C (Cyt c) [58]. Saikia et al. found that Cyt c could directly bind to tRNAs to form a ribonucleoprotein complex, block the oligomerization of Apaf-1 to ultimately inhibit the proliferation of ovarian cancer cells [53]. Resistance 3 (BCAR3) mRNA and hence reduce its expression, ultimately inhibiting the proliferation of ovarian cancer cells [53].

AURKA is a highly conserved serine kinase/threonine kinase that participates in the control of the cell cycle and is related to the regulation of some cell division-related biological processes [54]. Previous studies have shown that miRNA-137 and miRNA-32 can affect the progression of NSCLC by acting on AURKA [54, 55].

CU1276 is a representative tRF-3 that is overexpressed in mature B cells but repressed in lymphoma cell lines [40]. Stable expression of CU1276 in Burkitt lymphoma cells can inhibit cell proliferation, and when exogenous RPA1 is coexpressed, the proliferation of lymphoma cells can be restored. Similarly, the strong expression of CU1276 leads lymphoma cells to become more sensitive to drug-induced DNA damage. Restoration of RPA1 levels impeded this sensitization. These results suggested that CU176 inhibits lymphoma cell proliferation and is involved in DNA damage in an RPA1-dependent manner [40, 56].

Moreover, there is evidence suggesting that tRFs and tRNAs may regulate gene expression by binding to RBPs. tRFs from tRNA-Asp, tRNA-Glu, tRNA-Tyr, and tRNA-Gly can suppress cell growth under serum-starvation conditions by binding to YBX1, an RBP with multiple biological functions, and repressing its combination with some endogenous oncogene transcripts in breast cancer [57].
| tsRNA Type | Hallmark | Cancer type | Regulation mechanism | Reference |
|------------|----------|-------------|---------------------|-----------|
| tRF-Leu-CAG trRNA | Promote cell proliferation and cell cycle | NSCLC | Regulating AURKA | [45] |
| 5′-trNAVal trRNA | Promote Progression and lymph node metastasis | Breast cancer | Suppresses the Wnt/β-catenin signaling pathway by targeting FZD3 | [47] |
| ts-46 ts-47 trRF-1s | Inhibit cell proliferation | NSCLC | \ | [5] |
| tRNA-Glu tRNA-Asp tRNA-Gly tRNA-Tyr i-tRF | Inhibit cell proliferation and cancer metastasis | Breast cancer | YBX1 displacement | [57] |
| SHOT-RNAAsp-GUC | Promote cell proliferation and cancer metastasis | Breast cancer | Prostate cancer | \ | [24] |
| tRF/miR-1280 / | Inhibit cell proliferation, migration, and cancer stem cells phenotype | Colorectal Cancer | Repressing Notch signaling pathways | [64] |
| LeuCAG3′tsRNA trRF-3s | Promote cell apoptosis | Hepatocellular carcinoma | Binds two ribosomal protein mRNAs (RPS28 and RPS15) to enhance their translation | [61] |
| ts-3676 ts-4521 trRF-3s | Tumor suppressor | Lung cancer CLL | Interacting with Piwi Proteins | [41] |
| ts-43 ts-44 trRF-5s | Tumor suppressor | CLL | \ | [44] |
| tsRF-03357 | Promotes cell proliferation, migration, and invasion | High-grade serous ovarian cancer (HGSOC) | Modulating HMBOX1 in HGSOC | [52] |
| tsRF-Glu trRF-5s | Inhibit cell proliferation | Ovarian cancer | Regulates BCAR3 expression | [53] |
| tsRF-20-MONKSY93 trRNA | Inhibit cell migration and invasion | Colorectal cancer | Targeting Claudin-1 | [67] |
| tsRF-315 trRNA | Promote cisplatin resistance | Prostate cancer | Targeted the tumor suppressor gene GADD45A | [79] |
| tsRF-3017A trRF-3s | Promote the invasion and migration | Gastric cancer | Silencing Tumor suppressor NELL2 | [69] |
tsRNA-Leu-CAG 3’ could bind to at least two ribosomal protein mRNAs RPS28 and RPS15, and then promote their translation. Kim et al. found that tsRNA-Leu-CAG 3’ inhibition suppressed RPS28 translation which hindered the processing of 18S, and 40S was reduced [61]. Finally, the apoptosis of hepatoma cells was accelerated after tsRNA-Leu-CAG 3’ inhibition.

Cell migration and tumor metastasis

Metastasis is the main characteristic of malignant tumors, and it is a critical hallmark of tumor progression and poor prognosis. Uveal melanoma (UVM) is an intraocular malignant tumor with a metastatic rate of over 50%. After an analysis of 80 UVM samples, the expression of tRFs showed significant differences in the metastatic samples [62]. Samples with metastasis had a higher proportion of 18 nt tRFs and a lower proportion of 20 nt tRFs. In addition, M3 patients showed a higher expression of 18 nt tRFs [62]. A previous study found that by binding to the primer binding site of long terminal repeat-retrotransposons, 18-nt-long tRFs hinder reverse transcription and retrotransposon mobility, while 22-nt-long tRFs prevent transposon expression [63]. These results suggested that tRFs involved in tumor metastasis and tRFs of different lengths may have distinct functions in this malignant process.

One ncRNA called tRF/miR-1280 that is decreased in colorectal cancer tissues derived from both tRNA-Leu and pre-miRNA was identified as a regulator of colorectal cancer [64]. Huang et al. colleagues revealed that the overexpression of tRF/miR-1280 significantly inhibited the migration and mobility of colorectal cancer cells by preventing premetastatic niche (PMN) formation. It is widely believed that the PMN initiates angiogenesis and remodeling of the stroma and extracellular matrix [65]. In addition, Huang’s results showed that tRF/miR-1280 overexpression antagonized PMN formation by reducing the expression of CD31, MMP-2, and MMP-9. The endothelial–mesenchymal transition (EMT) is a malignant process and plays a critical role in the carcinogenesis and metastasis of cancers [66]. Recently, it was reported that tRF-20-M0NK5Y93 inhibited the EMT of colorectal cancer cells by targeting Claudin-1, thereby regulating the migration and invasion of colorectal cancer cells [67]. In another study, tRF-20-MEJB5Y13 was identified to be elevated in colorectal cancer under hypoxic conditions. This Dicer1-induced overexpression was demonstrated to be responsible for hypoxia-induced colorectal cancer invasion and migration [68].

Meanwhile, the metastasis regulatory functions of tSRNAs are also found in other malignancies. tRF-3017A was found to silence the tumor suppressor NELL2 through an AGO-dependent mechanism, thereby promoting the invasion and migration of gastric cancer cells [69]. tRF-17 was found to act as an invasion inhibitor by regulating the THBS1/THB51/smAD3 axis in breast cancer cells [70].

Tumor microenvironment

A growing body of evidence has demonstrated that tumor cells can produce extracellular vesicles such as microvesicles (EVs) and exosomes to communicate with other stromal cells by the transportation of ncRNAs and short-chain polypeptides [71]. This biological process can reshape the tumor microenvironment and facilitate tumor growth [72]. Recent studies have shown that EVs derived from cancer cells also include tRFs. In 2013, researchers reported the existence of tRNAs in human plasma exosomes for the first time [73]. A few years later, tRFs were found in EVs from breast cancer cells, glioma stem cells, and liver cancer cells [74–76]. These results suggest that TRFs may have critical roles in tumor microenvironment communication. However, no significant biological function of these exosome-derived TRFs has been identified thus far. Whether these TRFs in EVs can regulate angiogenesis, fibroblasts, or the immune environment of tumor cells remains to be determined.

Drug resistance

Drug resistance capacity is another important characteristic of cancer cells. There is emerging evidence implying that tRFs may be novel tumor drug resistance regulatory factors. Sun et al. demonstrated that tRF-30-JZOYJE22RR33 and tRF-27-ZDXP053SKN were correlated with trastuzumab resistance in breast cancer [77]. Another bioinformatic analysis showed that tDR-0009 (tDR-7336) might be involved in the chemoresistance and doxorubicin resistance of triple-negative breast cancer (TNBC) via regulation of STAT3 phosphorylation and the IL-6 response [78]. Moreover, tRF-315 derived from tRNA-Lys was demonstrated to be overexpressed in prostate cancer cells and relieved the cisplatin-induced apoptosis and mitochondrial dysfunction of these cancer cells by targeting the cell cycle-related gene GADD45A [79]. Therefore, research on the drug resistance functions of tRFs in cancer cells is in its early stages, and there will be more studies that reveal the mechanisms of tRF regulation of cancer drug resistance in the future.

Cancer stem cells

In the last decade, cancer stem cells (CSCs) have attracted increasing attention and become a new emerging hallmark of cancers. CSCs are a group of highly tumorigenic cancer cells that participate in many malignant biological functions such as EMT, tumor proliferation, and especially drug resistance and tumor recurrence [80]. In recent years, tRNA fragments have been proven to regulate protein translation and cell differentiation in somatic stem cells [32, 81]. Moreover, tRNA fragments were found to be critical for CSC functions in recent studies. tRF/miR-1280 was proven to reduce cell proliferation and colony formation and suppress CSC phenotypes via Notch signaling in colorectal cancer [64]. Wei et al. identified GluCTC and GlyCCC tRNA fragments that were enriched in microvesicles and exosomes from human glioma stem cells [75]. However, the molecular mechanisms of these two small RNAs in CSC functional regulation have barely been discussed.

Cancer metabolism

Energy metabolism in cancer cells is another noticeable hallmark of cancer disease. Recent studies reported that cancer cells can reprogram their glucose metabolism by suppressing the tricarboxylic acid cycle and enhancing glycolysis in the presence of oxygen, so-called “aerobic glycolysis” [82]. For the past few years, evidence has implied that tRNA fragments may have regulatory roles in the metabolic alterations of cancer cells. Researchers analyzed isoforms of miRNAs and tRNA fragments in TNBC and found that most dysregulated sncRNA-related mRNAs were enriched in oxidative phosphorylation and ribosome biogenesis [83]. One year later, another study published in the same journal showed that abnormally expressed tRF-related mRNAs were also correlated with glycolysis and ATP synthesis in almost all solid tumor types [84]. Moreover, other studies have also suggested the role of tRFs in protein biosynthesis in normal or tumor cells [32, 85].

In summary, although there is some evidence demonstrating the vital role of tRFs in metabolic alterations in cancer cells, deeper mechanistic insight into tRNA fragment regulation in this cancer hallmark are is needed.

APPLICATIONS OF TS RNAs IN CANCER DISEASES

Single tSRNAs as biomarkers or therapeutic targets of tumors

Early diagnosis of cancer is the key to obtaining improved treatment reactivity and prognosis. A growing body of evidence has demonstrated that miRNAs, cyclic RNAs, and long noncoding RNAs in exosomes have shown great potential as biomarkers for the diagnosis or prognosis of malignant diseases [86]. Recent studies have identified tSRNAs as a new kind of tumor biomarker,
other ncRNAs and circulating tumor DNAs (ctDNAs) (Table 2). The content of serum tsRNAs in liver cancer patients was significantly higher than that in healthy donors. Among the tsRNAs, tRNA-ValTAC-3, tRNA-Gly-TCC-5, tRNA-ValAAC-5, and tRNA-Glu-CTC-5 were the most significantly elevated [76]. Similarly, tRF-Leu-CAG was proven to be a potential marker for NSCLC, because it is significantly upregulated in NSCLC tissues, cell lines, and serum [45]. After screening differentially expressed tRNAs between lung cancer tissues and paracarcinoma tissues, Kuang et al. demonstrated that tRNA-Asn-ATT, tRNA-Ile-AAT, tRNA-Leu-TAA, mt-tRNA-Trp-TCA, mt-tRNA-Leu-TAA, tRNA-Pro-AGG, tRNA-Lys-CTT-1, and tRNA-Leu-AAG were associated with the clinicopathological characteristics of lung adenocarcinoma. Among them, tRNA-Lys-CTT-1, mt-tRNA-Ser-GCT, and tRNA-Tyr-ATA were associated with cancer-specific survival [87]. These specifically expressed tRFs can be used to construct prognostic models for lung cancer patients. Sun et al. found that tRF-30-JZOYE22RR33 and tRF-27-ZDXPHOS3KSN were highly expressed in trastuzumab-resistant cancer cells compared to trastuzumab-sensitive breast cancer cells [77]. Furthermore, the high levels of these two tRFs were related to shorter progression-free survival (PFS) of HER-2 positive breast cancer patients. These results indicated that tRF-30-JZOYE22RR33 and tRF-27-ZDXPHOS3KSN can be biomarkers and novel therapeutic targets for HER-2 positive breast cancer patients with trastuzumab resistance. Recently, researchers also found tRFs that act as biomarkers for the diagnosis and prognostic prediction in gastric cancer and myeloma [88–91].

| tsRNA | Cancer type | Characteristics | Reference |
|-------|-------------|-----------------|-----------|
| tRNA-ValTAC-3 | Liver cancer | All upregulating | [76] |
| tRNA-Gly-TCC-5 | | | |
| tRNA-ValAAC-5 | | | |
| tRNA-Glu-CTC-5 | | | |
| tRF-Leu-CAG | NSCLC | Upregulating | [45] |
| tRF-30-JZOYE22RR33 | Breast cancer | Upregulating | [77] |
| tRF-27-ZDXPHOS3KSN | TNBC | Upregulating | [95] |
| tRF-32-XSXM73VL4YK tRF-32-Q99P99NH57S | Breast cancer | Upregulating | [96] |
| tRF-32-Q99P99NH57S tRF-17-79MP9PP | | | |
| miR-21-5p miR-23a-3p | Breast cancer | All upregulating | [97] |
| tRF-Glu-CTC-003 tRF-Gly-CCC-007 | Breast cancer | All downregulating | [98] |
| tRF-Gly-CCC-008 tRF-Leu-CAA-003 tRF-Ser-TGA-001 tRF-Ser-TGA-002 | | | |
| tRF-Leu-CAG | NSCLC | Upregulating | [45] |
| ts-34 ts-49 | Breast cancer | Low level of ts-34 or a high level of ts-49 showed improved survival | [99] |
| miR-122-5p miR-142-3p 5’tRNA4-Val-AAC | Clear cell renal cell carcinoma | Upregulating | [100] |
| tRF-32-XSXMSL73VL4YK tRF-32-Q99P99NH57S | Breast cancer | Upregulating | [96] |
| tRF-32-Q99P99NH57S tRF-17-79MP9PP | | | |
| Multiple tsRNA expression signatures as risk factors | tRNAlysCTT tRNApheGAA | Prostate cancer | Upregulating | [101] |
| | | | Downregulating | |
patients [101]. In the future, more high-quality studies will construct more tRF signatures to predict other kinds of cancers.

CONCLUSION AND PERSPECTIVES

tRNAs are a novel group of ncRNAs and have critical roles in the development of most malignancies. They have been proven to regulate proliferation, apoptosis, migration, CSC phenotypes, and other vital cancer hallmarks. Meanwhile, emerging evidence implies that tRNAs may participate in the remodeling of the tumor microenvironment and control the metabolism and drug resistance capacity of cancer cells. Moreover, the application of tRNAs as cancer biomarker candidates and therapeutic targets is starting to receive more attention. Therefore, tRNA-related biological regulation in cancer disease will undoubtedly become a popular research topic in the future. However, there are also challenges to performing in-depth research on this regulatory network.

First, the database of tRNAs should be perfected. Although some online tRNA databases can provide the sequence and expression level of tRNAs in tumors, such as OncotRF, TRFExplorer, and tRFdb, the nomenclature of tRNAs has not been standardized [6, 26, 102]. Therefore, the search for tRNAs in the literature database is difficult and inefficient. Moreover, complementary pairing and target prediction information should be added to the database because it is important for research on miRNA-like mechanisms. Meanwhile, the molecular mechanisms of tRNA regulation remain to be explored. tRNAs can function as ncRNAs like miRNAs, but they exhibit much more complicated regulatory mechanisms. tRNAs regulatory patterns remain in case report-like summaries, especially RBP-related functions. In the future, the general pattern of tRNA regulation should be summarized.

Given the difficulties mentioned above, most of the current tRNA-related studies are superficial in terms of describing the detailed mechanisms involved in cancer hallmark regulation. Therefore, with novel understanding of tRNA regulatory mechanisms, more in-depth research on cancer hallmark regulation by tRNAs can provide an innovative view for the comprehension of cancer cell biology.

DATA AVAILABILITY

All data included in this study are available upon request by contact with the corresponding author.

REFERENCES

1. Zhu L, Ge J, Li T, Shen Y, Guo J. tRNA-derived fragments and tRNA halves: the new players in cancers. Cancer Lett. 2019;452:31–7.
2. Schimmel P. The emerging complexity of the tRNA world: mammalian tRNAs beyond protein synthesis. Nat Rev Mol Cell Biol. 2018;19:45–58.
3. Abbott JA, Franklyn CS, Robey-Bond SM. Transfer RNA and human disease. Front Genet. 2014;5:158.
4. Speer J, Gehrke CW, Kuo KC, Waalikes TP, Borek E. tRNA breakdown products as markers for cancer. Cancer 1979;44:2120–1.
5. Balatti V, Nigita G, Veneziano D, Drusco A, Stein GS, Messier TL, et al. tRNA dependent viral gene expression by pre-tRNA 3'-trailer-derived tRNA fragments. Nucleic Acids Res. 2015;43:141–5.
6. Kumar P, Mudunuri SB, Anaya J, Dutta A. tRFdb: a database for transfer RNA fragments. Nucleic Acids Res. 2015;43:D141–5.
7. Kumar P, Anaya J, Mudunuri S, Dutta A. Meta-analysis of tRNA derived RNA fragments reveals that they are evolutionarily conserved. BMC Biol. 2014;12:78.
8. Wang Q, Lee J, Ren J, Ajay SS, Lee YS, Bao X. Identification and functional characterization of tRNA-derived RNA fragments (tRFs) in respiratory syncytial virus infection. Mol Ther. 2013;21:368–79.
9. Cho H, Lee W, Kim GW, Lee SH, Moon JS, Kim M, et al. Regulation of La/SSB-dependent viral gene expression by pre-tRNA 3’ trailer-derived tRNA fragments. Nucleic Acids Res. 2019;47:9888–901.
10. Yeung ML, Bennasser Y, Watsaki K, Le SY, Houzet L, Jeang KT. Pyrosequencing of small non-coding RNAs in HIV-1 infected cells: evidence for the processing of a viral-cellular double-stranded RNA hybrid. Nucleic Acids Res. 2000;28:6575–86.
11. Deng J, Pashkin RN, Chen Y, Cheng Z, Liu G, Phan T, et al. Respiratory syncytial virus utilizes a tRNA fragment to suppress antiviral responses through a novel targeting mechanism. Mol Ther. 2015;23:1622–9.
12. Telonis AG, Loher P, Magee R, Platiakos V, Londin E, Kirino Y, et al. tRNA fragments show intertwining with miRNAs of specific repeat content and have links to disparities. Cancer Res. 2019;79:3034–49.
13. Irwana N, Schwam H, Chambers RW. Transfer RNA 3’. Reconstitution of alanyl acceptor activity from fragments produced by specific cleavage of tRNA Ala-Il at its anticodon. Proc Natl Acad Sci USA. 1969;62:1203–9.
14. Li S, Xu Z, Sheng J. tRNA-derived small RNA: a novel regulatory small non-coding RNA. Genes. 2018;19:246.
15. Saikia M, Krokowski D, Guan BJ, Ivanov P, Parisien M, Hu GF, et al. Genome-wide identification and quantitative analysis of cleaved tRNA fragments induced by cellular stress. J Biol Chem. 2012;287:4207–28.
16. Li Z, Ender C, Meister G, Moore PS, Chang Y, John B. Extensive terminal and asymmetric processing of small RNAs from rRNAs, snoRNAs, snRNAs, and tRNAs. Nucleic Acids Res. 2012;40:6787–99.
17. Zhu P, Yu J, Zhou P. Role of tRNA-derived fragments in cancer: novel diagnostic and therapeutic targets tRFs in cancer. Am J Cancer Res. 2020;10:393–402.
18. Xie Y, Yao L, Yu X, Ruan Y, Li Z, Guo J. Action mechanisms and research methods of tRNA-derived small RNAs. Signal Transduct Target Ther. 2020;5:109.
19. Cole C, Sobala A, Lu C, Thatcher SR, Bowman A, Brown JW, et al. Filtering of deep sequencing data reveals the existence of abundant Dicer-dependent small RNAs derived from tRNAs. RNA 2009;15:2147–60.
20. Phizicky EM, Hopper AK. tRNA biology charges to the front. Genes Dev. 2010;24:1832–60.
21. Lee YS, Shibata Y, Malhotra A, Dutta A. A novel class of small class of small RNAs: tRNA-derived RNA fragments (tRFs). Genes Dev. 2009;23:2639–49.
22. Markc C, Grosjean H. tRNomics: analysis of tRNA genes from 50 genomes of Eukarya, Archaea, and Bacteria reveals anticond-sparing strategies and domain-specific features. RNA 2002;8:1189–232.
23. Kim HK, Yeom JH, Kay MA. Transfer RNA-derived small RNAs: another layer of gene regulation and novel targets for disease therapeutics. Mol Ther. 2020;28:2340–57.
24. Honda S, Loher P, Shigematsu M, Palazzo JP, Suzuki R, Imoto I, et al. Sex hormone-dependent tRNA halves enhance cell proliferation in breast and prostate cancers. Proc Natl Acad Sci USA. 2015;112:E3816–25.
25. Xu J, He X, Liu C, Liu J, Hu Q, Pan T, et al. IL-4 inhibits the biogenesis of an epigenetically suppressive PIWI-interacting RNA to upregulate CD11a molecules on monocytes/dendritic cells. J Immunol. 2016;196:1591–603.
26. Yao D, Sun X, Zhou L, Amannullah M, Pan X, Liu Y, et al. OncotRF: an online resource for exploration of tRNA-derived fragments in human cancers. RNA Biol. 2020;17:1081–91.
27. Gebetsberger J, Zywicki M, Kunzi A, Polacek N. tRNA-derived fragments target the ribosome and function as regulatory non-coding RNA in Haloferax volcanii. Archaea 2012;2012:260909.
28. Sobala A, Huvtagner G. Small RNAs derived from the 5’ end of tRNA can inhibit protein translation in human cells. RNA Biol. 2013;10:553–63.
29. Flores J, Hussain S, Kutter C, Humphreys P, et al. Aberrant methylation of tRNA: links cellular stress to neuro-developmental disorders. EMBO J. 2011;34:2020–39.
30. Ivanov P, Emara MM, Villen J, Gygi SP, Anderson P. Angiogenin-induced tRNA fragments inhibit translation initiation. Mol Cell. 2011;43:613–23.
31. Emara MM, Ivanov P, Hickman T, Dawra N, Tisdale S, Kedersha N, et al. Argiogín-induced tRNA-derived stress-induced small RNAs promote stress-induced stress granule assembly. J Biol Chem. 2010;285:10959–68.
32. Lyons SM, Gudanis D, Coyne SM, Gdaniec Z, Ivanov P. Identification of functional tetramolecular RNA G-quadruplexes derived from transfer RNAs. Nat Commun. 2017;8:1127.
33. Lyons SM, Gudanis D, Coyne SM, Gdaniec Z, Ivanov P. Identification of functional tetramolecular RNA G-quadruplexes derived from transfer RNAs. Nat Commun. 2017;8:1127.
34. Couvillion MT, Sachidanandam R, Collins K. A growth-essential Tetrahymena Piwi protein carries tRNA fragment cargo. Genes Dev. 2010;24:2742–7.
35. Kumar P, Anaya J, Mudunuri SB, Dutta A. Meta-analysis of tRNA derived RNA fragments reveals that they are evolutionarily conserved and associate with AGO proteins to recognize specific RNA targets. BMC Biol. 2014;12:78.
36. Kuscu C, Kumar P, Kiran M, Su Z, Malik A, Dutta A. tRNA fragments (tRFs) guide Ago to regulate gene expression post-transcriptionally in a Dicer-independent manner. RNA 2018;24:1093–105.
37. Burroughs AM, Ando Y, de Hoon M, Tomaru Y, Suzuki H, Hayashizaki Y, et al. Deep-sequencing of human Argonaute-associated small RNAs provides insight into miRNA sorting and reveals Argonaute association with RNA fragments of diverse origin. RNA Biol. 2011;8:158–77.
38. Guan L, Karaiskos S, Grigoriev A. Inferring targeting modes of Argonaute-loaded tRNA fragments. RNA Biol. 2020;17:1070–80.
39. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001;409:363–6.
40. Maute RL, Schneider C, Sumarzine H, Calafano A, Bassi K, et al. tRNA-derived microRNA modulates proliferation and the DNA damage response and is deregulated in diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2013;110:1404–9.
41. Pekarsky Y, Balatti V, Hallem A, Rizzotto L, Veneziano D, Nigita G, et al. Dysregulation of a family of short noncoding RNAs, tRNAs, in human cancer. Proc Natl Acad Sci USA. 2016;113:5071–6.
42. Siomi MC, Sato K, Pezic D, Aravin AA. PIWI-interacting small RNAs: the vanguard of genome defense. Nat Rev Mol Cell Biol. 2011;12:246–58.
43. Hasler D, Lehmann G, Murakawa Y, Klironomos F, Jakob L, Grasser FA, et al. Characterization of cytoplasmic tRNA and tRNA-derived fragments suppress breast cancer progression via YBX1 displacement. Mol Cell. 2016;63:110–24.
44. Venizeano D, Tomasello L, Balatti V, Palamarachik A, Rassenti LZ, Kipps TJ, et al. Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2011;108:24252–2.
45. Shao Y, Sun Q, Liu X, Wang P, Wu R, Ma Z. tRF-Leu-CAG promotes cell proliferation and cell cycle in non-small cell lung cancer. Chem Biol Drug Des. 2017;90:730–8.
46. Huang Y, Ge H, Zheng M, Cui Y, Fu Z, Wu X, et al. Serum tRNA-derived fragments (tRFs) as potential candidates for diagnosis of nontriple negative breast cancer. J Cell Physiol. 2020;235:2809–24.
47. Mo D, Jiang P, Yang Y, Mao X, Tan X, Tang X, et al. A tRNA fragment, 5'-tRNA (Val), suppresses the Wnt/beta-catenin signaling pathway by targeting FZD3 in breast cancer. Cancer Lett. 2019;457:60–73.
48. Selitsky SR, Baran-Gale J, Honda M, Yamane D, Masaki T, Fannin EE, et al. Small tRNA-derived RNAs are increased and more abundant than microRNAs in chronic hepatitis B and C. Sci Rep. 2015;5:7675.
49. Papadimitriou MA, Avgeris M, Levis P, Papasotiriou EC, Kotronopoulos G, et al. Circulating tRNA-derived RNAs are increased and more abundant than microRNAs in chronic hepatitis B and C. Sci Rep. 2015;5:7675.
50. Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJ, Moller S, Trapman J, et al. tRNA fragments and tRNA-derived fragments suppress apoptosis during osmotic stress. Mol Cell Biol. 2014;34:2450–63.
51. Zhou K, Diebel KW, Holy J, Skildum A, Odean E, Hicks DA, et al. A tRNA fragment, tRF5-Glu, regulates BCAR3 expression and proliferation in ovarian cancer cells. Cell Death Dis. 2018;9:419–31.
52. Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2017;387:61–8.
53. Huang X, Yuan T, Tschannen M, Sun Z, Jacob H, Du M, et al. Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics. 2013;14:319.
54. Guan L, Karaiskos S, Grigoriev A. Inferring targeting modes of Argonaute-loaded tRNA fragments suppress breast cancer progression via YBX1 displacement. Mol Cell. 2016;63:110–24.
55. Xiong J, Mason AC, Binz SK, Wold MS. Cellular functions of human RPA1. Multiple roles of domains in replication, repair, and checkpoints. J Biol Chem. 2008;283:19095–111.
56. Goodarzi H, Liu X, Nguyen HC, Zhang S, Fish L, Tavazoie SF. Endogenous tRNA-dependent fragments suppress breast cancer progression via YBX1 displacement. Cell 2015;161:790–802.
57. Mei Y, Yong J, Liu H, Shi Y, Meinloch J, Dreyfuss G, et al. tRNA binds to cytochrome c and inhibits caspase activation. Mol Cell. 2010;37:668–78.
58. Saikia M, Jobava R, Parisien M, Putnam A, Krokowski D, Gao XH, et al. tRNA-derived microRNA modulates proliferation and the DNA damage response and is deregulated in diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2013;110:1404–9.
59. Pekarsky Y, Balatti V, Palamarachik A, Rizzotto L, Veneziano D, Nigita G, et al. Dysregulation of a family of short noncoding RNAs, tRNAs, in human cancer. Proc Natl Acad Sci USA. 2016;113:5071–6.
60. Xiong J, Mason AC, Binz SK, Wold MS. Cellular functions of human RPA1. Multiple roles of domains in replication, repair, and checkpoints. J Biol Chem. 2008;283:19095–111.
92. Peng Z, Chen Y, Cao H, Zou H, Wan X, Zeng W, et al. Protein disulfide isomerases are promising targets for predicting the survival and tumor progression in glioma patients. Aging. 2020;12:2347–12.

93. Zeng D, Li M, Zhou R, Zhang J, Sun H, Shi M, et al. Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures. Cancer Immunol Res. 2019;7:375–50.

94. Xu F, Chen J-X, Yang X-B, Hong X-B, Li Z-X, Lin L, et al. Analysis of lung adenocarcinoma subtypes based on immune signatures identifies clinical implications for cancer therapy. Mol Ther Oncolytics. 2020;17:241–9.

95. Cui Y, Huang Y, Wu X, Zheng M, Xia Y, Fu Z, et al. Hypoxia-induced tRNA-derived fragments, novel regulatory factor for doxorubicin resistance in triple-negative breast cancer. J Cell Physiol. 2019;234:8740–51.

96. Wang X, Yang Y, Tan X, Mao X, Wei D, Yao Y, et al. Identification of tRNA-derived fragments expression profile in breast cancer tissues. Curr Genomics. 2019;20:199–213.

97. Koi Y, Tsutani Y, Nishiyama Y, Ueda D, Ibuki Y, Sasada S, et al. Predicting the presence of breast cancer using circulating small RNAs, including those in the extracellular vesicles. Cancer Sci. 2020;111:2104–15.

98. Wang J, Ma G, Li M, Han X, Xu J, Liang M, et al. Plasma tRNA fragments derived from 5' ends as novel diagnostic biomarkers for early-stage breast cancer. Mol Ther Nucleic Acids 2020;21:954–64.

99. Shan N, Li N, Dai Q, Hou L, Yan X, Amei A, et al. Interplay of tRNA-derived fragments and T cell activation in breast cancer patient survival. Cancers. 2020;12:2230.

100. Niemietz D, Deng M, Schmidt D, Perner S, Müller SC, Ellinger J. Identification of aberrant tRNA-halves expression patterns in clear cell renal cell carcinoma. Sci Rep. 2016;6:37158.

101. Olvedy M, Scaravilli M, Hoogstrate Y, Visakorpi T, Jenster G, Martens-Uzunova ES. A comprehensive repertoire of tRNA-derived fragments in prostate cancer. Oncotarget 2016;7:24766–77.

102. La Ferlita A, Alaimo S, Veneziano D, Nigita G, Balatì V, Croce CM, et al. Identification of tRNA-derived ncRNAs in TCGA and NC-60 panel cell lines and development of the public database tRFexplorer. Database. 2019;2019:baz115.

ACKNOWLEDGEMENTS
Thanks for the generous support of National Natural Science Foundation of China (No. 81974367, No. 81572281, No. 81702278, No. 82003065), the National Natural Science Foundation of Hunan Province (No. 2020JJ4132), and National Multi-disciplinary Cooperative Diagnosis and Treatment Capacity Building Project for Major Diseases (Lung Cancer).

AUTHOR CONTRIBUTIONS
Xuhe Li and Xianyu Liu performed manuscript writing and figure drawing; Deze Zhao performed literature research; Weifang Cui performed manuscript preparation; Yingfang Wu performed manuscript editing; Chaojun Duan and Chunfang Zhang contributed to the conception and review of the paper.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41420-021-00647-1.

Correspondence and requests for materials should be addressed to Chunfang Zhang or Chaojun Duan.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021